Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04229030 · ClinicalTrials.gov registry record · Phase 2
RZL-012 for Dercum's Disease Lipomas
A Phase 2 study of Dercum's Disease Lipomas, sponsored by Raziel Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT04229030: Completed Phase 2 study of Dercum's Disease Lipomas, sponsored by Raziel Therapeutics.
NCT04229030 is a Phase 2 study of Dercum's Disease Lipomas that has completed, run by Raziel Therapeutics. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04229030, a Phase 2 study of Dercum's Disease Lipomas, has completed, sponsored by Raziel Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
Thirty-eight (38) subjects will be included in the study. Subjects will be randomized in a ration of 1:1 to be treated with RZL-012 or placebo. Subjects will be injected with a different doses of RZL-012 according to their lipomas sizes. The total of 38 subjects will be enrolled in 3 clinical sites.
Primary Outcome
Evaluation of the efficacy of RZL-012 following injection into lipomas/nodules of Dercum's Disease (DD) subjects. Efficacy will be determined by ultrasound assessment of the lipoma/nodule dimensions after treatment vs baseline. Lipomas Dimensions will be measured for active vs. placebo at days 28,56,84
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG RZL-012
Study Locations (1)
California
- Limitless Therapeutics - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-07-30 |
| Est. Completion | 2021-02-20 |
| Phase | Phase 2 |
What the finished NCT04229030 record still lists
NCT04229030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Dercum's Disease Lipomas appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT04229030 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04229030 about?
NCT04229030 is a clinical study titled "RZL-012 for Dercum's Disease Lipomas". Thirty-eight (38) subjects will be included in the study. Subjects will be randomized in a ration of 1:1 to be treated with RZL-012 or placebo. Subjects will be injected with a different doses of RZL-012 according to their lipomas sizes. The total of 38 subjects will be enrolled in 3 clinical sites.
What is the current status of trial NCT04229030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2020-07-30. Estimated completion is 2021-02-20.
What conditions does trial NCT04229030 study?
This clinical trial studies the following conditions: Dercum's Disease Lipomas.
What interventions are being tested in trial NCT04229030?
The interventions under investigation include: Vehicle (DRUG), RZL-012 (DRUG).
Who is sponsoring clinical trial NCT04229030?
This trial is sponsored by Raziel Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04229030 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04229030's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI